CryoPort to Announce Q4 Earnings on March 3rd
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy CYRX?
Source: seekingalpha
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYRX
Wall Street analysts forecast CYRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.420
Low
11.00
Averages
11.00
High
11.00
Current: 8.420
Low
11.00
Averages
11.00
High
11.00
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
Cryoport Launches Fusion 800 Series, Revolutionizing Cryogenic Storage Technology
- Technological Innovation: Cryoport has launched the Fusion 800 Series through its MVE Biological Solutions division, which operates without the need for continuous liquid nitrogen, providing a compact and efficient cryogenic storage solution that addresses the space and infrastructure demands of traditional systems.
- Design Advantages: The Fusion 800's compact design (32 inches wide) allows it to fit through standard door frames, avoiding costly facility modifications, significantly reducing operational complexity while enhancing safety and flexibility.
- Financial Performance: In November, Cryoport reported Q3 revenue of $44.2 million, exceeding analyst expectations of $41.36 million, with a year-over-year growth of 15%, including a 36% increase in Commercial Cell and Gene Therapy, indicating strong market demand.
- Future Outlook: Cryoport raised its fiscal 2025 revenue guidance to a range of $170 million to $174 million, reflecting confidence in the market potential of the Fusion 800 Series and the overall growth of the company.
See More
Cryoport Launches Self-Sustaining Cryogenic Freezer
- Product Launch: Cryoport has unveiled the MVE Fusion®800 Series self-sustaining cryogenic freezer, eliminating the need for a continuous liquid nitrogen supply, which enhances reliability and safety in space-constrained environments, potentially setting a new industry standard for biological material storage.
- Space Efficiency: With a width of just 32 inches, the Fusion 800 can easily fit through standard doorways for installation, avoiding costly facility modifications typically required by traditional cryogenic systems, thereby reducing infrastructure burdens for customers and increasing market adoption.
- Wide Application Potential: This freezer is ideal for medical research facilities, clinical development, hospital pharmacies, and more, maintaining steady temperatures at or below -150°C, which meets stringent storage requirements for biological samples and life-saving therapies, likely encouraging more facilities to adopt true cryogenic storage.
- Industry Recognition: MVE's Fusion technology has received the ISBER Outstanding New Product Award, highlighting Cryoport's innovative capabilities in cryogenic storage, and the Fusion 800 is expected to become the new standard in research facilities and hospital pharmacies worldwide, further solidifying Cryoport's leadership in the life sciences supply chain.
See More
Cryoport Launches MVE Fusion 800 Series Freezer
- Product Innovation: Cryoport's MVE Fusion 800 Series freezer features a self-sustaining design that eliminates the need for a continuous liquid nitrogen supply, delivering exceptional reliability and safety in space-constrained environments, which is expected to set a new industry standard for biological material storage.
- Space Efficiency: With a width of only 32 inches, the freezer can easily fit through standard doorways for installation, avoiding costly facility modifications, significantly enhancing operational flexibility and storage density to meet the needs of medical research and clinical development.
- Industry Recognition: The MVE Fusion technology has received the ISBER Outstanding New Product Award, marking its innovative position in cryogenic storage, and Cryoport believes the Fusion 800 is on track to become the new standard in research facilities and hospital pharmacies worldwide.
- Versatile Storage: The Fusion 800 is suitable for storing various biological materials, including blood bags and vials, maintaining steady temperatures at or below -150°C, thereby meeting the demands of biostorage and clinical needs, further driving the company's market share in the life sciences sector.
See More
Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
Cryoport Launches Fusion 800 Series, Revolutionizing Cryogenic Storage Technology
- Technological Innovation: Cryoport has launched the Fusion 800 Series through its MVE Biological Solutions division, which operates without the need for continuous liquid nitrogen, providing a compact and efficient cryogenic storage solution that addresses the space and infrastructure demands of traditional systems.
- Design Advantages: The Fusion 800's compact design (32 inches wide) allows it to fit through standard door frames, avoiding costly facility modifications, significantly reducing operational complexity while enhancing safety and flexibility.
- Financial Performance: In November, Cryoport reported Q3 revenue of $44.2 million, exceeding analyst expectations of $41.36 million, with a year-over-year growth of 15%, including a 36% increase in Commercial Cell and Gene Therapy, indicating strong market demand.
- Future Outlook: Cryoport raised its fiscal 2025 revenue guidance to a range of $170 million to $174 million, reflecting confidence in the market potential of the Fusion 800 Series and the overall growth of the company.
See More
Cryoport Launches Self-Sustaining Cryogenic Freezer
- Product Launch: Cryoport has unveiled the MVE Fusion®800 Series self-sustaining cryogenic freezer, eliminating the need for a continuous liquid nitrogen supply, which enhances reliability and safety in space-constrained environments, potentially setting a new industry standard for biological material storage.
- Space Efficiency: With a width of just 32 inches, the Fusion 800 can easily fit through standard doorways for installation, avoiding costly facility modifications typically required by traditional cryogenic systems, thereby reducing infrastructure burdens for customers and increasing market adoption.
- Wide Application Potential: This freezer is ideal for medical research facilities, clinical development, hospital pharmacies, and more, maintaining steady temperatures at or below -150°C, which meets stringent storage requirements for biological samples and life-saving therapies, likely encouraging more facilities to adopt true cryogenic storage.
- Industry Recognition: MVE's Fusion technology has received the ISBER Outstanding New Product Award, highlighting Cryoport's innovative capabilities in cryogenic storage, and the Fusion 800 is expected to become the new standard in research facilities and hospital pharmacies worldwide, further solidifying Cryoport's leadership in the life sciences supply chain.
See More
Cryoport Launches MVE Fusion 800 Series Freezer
- Product Innovation: Cryoport's MVE Fusion 800 Series freezer features a self-sustaining design that eliminates the need for a continuous liquid nitrogen supply, delivering exceptional reliability and safety in space-constrained environments, which is expected to set a new industry standard for biological material storage.
- Space Efficiency: With a width of only 32 inches, the freezer can easily fit through standard doorways for installation, avoiding costly facility modifications, significantly enhancing operational flexibility and storage density to meet the needs of medical research and clinical development.
- Industry Recognition: The MVE Fusion technology has received the ISBER Outstanding New Product Award, marking its innovative position in cryogenic storage, and Cryoport believes the Fusion 800 is on track to become the new standard in research facilities and hospital pharmacies worldwide.
- Versatile Storage: The Fusion 800 is suitable for storing various biological materials, including blood bags and vials, maintaining steady temperatures at or below -150°C, thereby meeting the demands of biostorage and clinical needs, further driving the company's market share in the life sciences sector.
See More
Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
